The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

Valerio only has cash to last three months, according to the DNA decoy specialist. The news comes less than six months after ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

At the J.P. Morgan Healthcare Conference, the Biotech Sisterhood assembled in Union Square to showcase the large group of ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...

Senator Bill Cassidy voted with fellow Republicans on the Senate Finance Committee Tuesday morning to move forward the ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...